Document is current
Any future updates will be listed below
-
Authors
Brown, C. Hendricks https://orcid.org/0000-0002-0294-2419
Smith, J. D.
Haegerich, Tamara
Simon, Gregory
Cero, Ian
Aarons, Gregory
Prado, Guillermo
Wyman, Peter
Kane, John
Robinson, Delbert
Walunas, Theresa L.
Zimmerman, Lindsey
Vermeer, Wouter
Chin-Purcell, Lia
McNulty, Moira
Christopoulos, Katerina A.
Garner, Bryan
McGovern, Mark
-
Funding
Funding for this research was provided by:
National Institute on Drug Abuse (U2CDA057717)
National Institute on Drug Abuse (P50DA054072)
National Institute on Drug Abuse (P30DA027828)
National Institute on Drug Abuse (R01DA046651)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (P30AR072579)
National Institute of Mental Health (P50MH132502)
National Institute of Mental Health (R01MH140440)
National Institute of Mental Health (R01MH124718)
National Institute of Mental Health (R01MH131738)
National Center for Advancing Translational Sciences (UM1TR005121)
Agency for Healthcare Research and Quality (U18HS027953)
U.S. Department of Veterans Affairs (I01HX002521)
- License Information
-
More Information
Article History
Received: 22 April 2025
Accepted: 10 October 2025
First Online: 11 December 2025
Declarations
:
: While all implementation trials referred to in this paper have been approved by a home Institutional Review Board, this methodology paper does not include any new studies or analyses and therefore has no participants. Rollout trials themselves are designed to address ethical issues so that no site is withheld from an evidence-based intervention across the entire trial.
: This paper has been reviewed before submission by the National Institute on Drug Abuse as one of the authors (TH) is employed there, and this follows established policies. All authors consent to publication as well.
: C.H. Brown, as director of the National Institute on Drug Abuse (NIDA) funded P30, Center for Prevention Implementation Methodology, led the development of innovative rollout designs for implementation, and he has served as the lead methodologist on a number of implementation trials; he is also the current director of the Research Core of the Center for Dissemination and Implementation at Stanford (CDIAS), a NIDA funded P50 and MPI of the Research and Evaluation Core of the NIDA funded HD2A Research Adoption Support Center (RASC). C H Brown is also on the Editorial Board of Implementation Science. J.D. Smith is an Associate Editor of Implementation Science . Gregory A. Aarons is co-Editor-in Chief at Implementation Science and is on the editorial board of Implementation Science Communications. All manuscript handling and decisions about this paper were made by other editors.The University of Miami and Dr. Guillermo Prado are the owners and inventor of trademarked materials used in the Familias Unidas intervention, and both may receive royalties for its commercialization. T.L. Walunas has received research funding for unrelated work from Gilead Sciences. D Robinson has been a consultant to Acadia, Advocates for Human Potential, Amalyx, American Psychiatric Association, C4 Innovations, Costello Medical Consulting, Eli Lilly, Health Analytics, Karuna, Innovative Science Solutions, Janssen, Lykos, Lundbeck, Neurocrine, Neuronix, Otsuka, Teva and US WorldMeds. L Zimmerman serves as the co-director of the Design and Modeling Section of the NIDA funded C-DIAS. M McNulty served on an advisory board for Gilead Sciences. K. A. Christopoulos served as a workshop participant for Janssen. M McGovern is PI of the aforementioned CDIAS and PI for the RASC.The following people have declared no completing interests: Ian Cero, Wouter Vermeer, Bryan Garner, and Lia Chin-Purcell.
